1. Propofol produces a dose-dependent reduction in mean arterial pressure after an induction bolus, typically 25 to 40%. Which combination of mechanisms is responsible?
A) Peripheral vasodilation through reduced systemic vascular resistance, a direct reduction in myocardial contractility, and blunting of the baroreceptor reflex that would otherwise produce a compensatory tachycardia — all three mechanisms act simultaneously to produce the hemodynamic depression.
B) Selective negative chronotropy through direct sinoatrial node depression, without any effect on vascular resistance or myocardial contractility — the fall in MAP is driven entirely by the reduction in cardiac output from bradycardia.
C) Cerebral vasodilation reducing cerebrovascular resistance and redistributing cardiac output toward the cerebral circulation, secondarily reducing systemic perfusion pressure and MAP without any direct cardiac or peripheral vascular effect.
D) Inhibition of central sympathetic outflow from the rostral ventrolateral medulla, producing simultaneous arteriolar dilation and venodilation — MAP falls because of the combined reduction in preload and afterload, while contractility is fully preserved.
E) Direct coronary vasodilation reducing myocardial oxygen delivery, triggering a reflex reduction in cardiac output as a protective mechanism against ischemia — the hypotension is a homeostatic response rather than a primary pharmacological effect.
ANSWER: A
Rationale:
Option A is correct. Propofol's cardiovascular depression results from three simultaneous mechanisms. First, it reduces systemic vascular resistance through peripheral vasodilation, lowering afterload and MAP. Second, it has a direct negative inotropic effect on myocardial contractility, reducing stroke volume and cardiac output. Third — and clinically important — it blunts the baroreceptor reflex, so the tachycardia that would normally compensate for the fall in blood pressure either does not occur or is attenuated; propofol may also have a mild direct negative chronotropic effect. The combination of all three mechanisms explains why propofol-induced hypotension is more pronounced than would be expected from vasodilation alone, and why dose reduction and slow administration are required in elderly, hypovolemic, or left-ventricular-impaired patients.
Option B: Option B is incorrect; while propofol does affect heart rate through baroreceptor blunting and mild chronotropic depression, selective SA node depression as the sole mechanism does not explain the full hemodynamic profile — vasodilation and reduced contractility are both independently documented.
Option C: Option C is incorrect; propofol actually reduces cerebral blood flow in parallel with reducing CMRO2 — it does not cause cerebral vasodilation, and redistribution of cardiac output toward the brain is not a mechanism of systemic hypotension with propofol.
Option D: Option D is incorrect; while central sympatholysis contributes to propofol's hemodynamic effects, the characterization that contractility is fully preserved is inaccurate — propofol has a direct negative inotropic component that is independent of its vascular effects.
Option E: Option E is incorrect; propofol-induced hypotension is a primary pharmacological effect of its GABA-A-mediated cardiovascular actions, not a reflex homeostatic response to coronary vasodilation.
2. Myoclonus — involuntary, brief, shock-like muscle jerks — occurs in 30 to 70% of patients during induction with etomidate when no premedication is given. Which statement most accurately characterizes this phenomenon and its clinical management?
A) Etomidate-induced myoclonus represents subcortical seizure activity originating in the thalamus, driven by the same mechanism that causes spike-wave discharges in absence epilepsy — it requires immediate treatment with IV lorazepam to terminate the ictal activity before it generalizes.
B) Myoclonus during etomidate induction is caused by direct stimulation of spinal motor neurons through etomidate's partial agonist activity at glycine receptors in the ventral horn, producing segmental disinhibition — it is prevented by pretreatment with a non-depolarizing neuromuscular blocking agent.
C) Etomidate-induced myoclonus reflects GABA-A receptor hypersensitivity in patients with subclinical epilepsy, unmasked by etomidate's positive allosteric modulation — its occurrence identifies patients at high risk for postoperative seizures and warrants neurological evaluation before proceeding.
D) Etomidate-induced myoclonus is a cortical disinhibition phenomenon — it does not represent seizure activity and is not associated with EEG epileptiform discharges; it occurs because etomidate inhibits subcortical structures before fully suppressing the cortex, transiently releasing cortical neurons from inhibitory control. Incidence is substantially reduced by pretreatment with fentanyl 1 to 2 mcg/kg IV or midazolam 1 to 2 mg IV administered before induction.
E) Myoclonus during etomidate induction is caused by adrenocortical suppression reducing circulating cortisol below the threshold needed to suppress excitatory neurotransmission — it is a prodrome of acute adrenal crisis and mandates immediate hydrocortisone administration before any further anesthetic is given.
ANSWER: D
Rationale:
Option D is correct. Etomidate-induced myoclonus is well characterized as a cortical disinhibition phenomenon — it is not seizure activity and is not accompanied by epileptiform EEG discharges. The mechanism reflects differential suppression: etomidate inhibits subcortical inhibitory structures before achieving full cortical suppression, transiently releasing cortical motor neurons from tonic inhibitory control and producing the involuntary muscle jerks. While it is alarming to observe, it carries no epileptic significance. Its clinical importance is practical — it can interfere with IV cannula placement, cause patient injury if vigorous, and is distressing to observers. Pretreatment with fentanyl 1 to 2 mcg/kg IV or midazolam 1 to 2 mg IV administered 2 to 3 minutes before induction substantially reduces incidence and severity.
Option A: Option A is incorrect; etomidate myoclonus is not thalamic seizure activity and does not require benzodiazepine treatment to terminate ictal discharges — treating it as a seizure is both pharmacologically inaccurate and clinically unnecessary.
Option B: Option B is incorrect; etomidate does not act as a partial agonist at glycine receptors — its primary mechanism is GABA-A positive allosteric modulation, and myoclonus is not caused by spinal ventral horn disinhibition through glycinergic pathways; neuromuscular blockade would abolish the visible movement but does not address the underlying mechanism.
Option C: Option C is incorrect; etomidate-induced myoclonus does not identify subclinical epilepsy and does not require neurological evaluation — it occurs in the majority of unpremedicated patients regardless of seizure history and has no predictive value for postoperative seizure risk.
Option E: Option E is incorrect; adrenocortical suppression from etomidate is a separate, delayed effect on steroidogenesis — it is not the mechanism of myoclonus and does not manifest as myoclonus; the onset of cortisol suppression is biochemical and occurs over hours, not seconds.
3. A patient with acute severe asthma is in the emergency department with progressive respiratory failure unresponsive to bronchodilator therapy and requires emergency intubation. Which induction agent is preferred and what property makes it the choice in this specific scenario?
A) Propofol — at induction doses it produces direct bronchial smooth muscle relaxation through GABA-A-mediated inhibition of vagal bronchoconstrictor tone in the airway ganglia, making it the most potent bronchodilator among the IV induction agents.
B) Ketamine — it is a potent bronchodilator that relaxes bronchial smooth muscle through its sympathomimetic mechanism (catecholamine release and reuptake inhibition increasing adrenergic tone at airway smooth muscle beta-2 receptors) and possibly through direct smooth muscle relaxation, making it the induction agent of choice for emergency airway management in patients with acute severe asthma or status asthmaticus.
C) Etomidate — it produces hemodynamic stability without any effect on airway smooth muscle tone, ensuring that induction does not worsen bronchospasm through hypotension-mediated reflex vagal activation, making it the safest bronchospasm-neutral choice in this scenario.
D) Thiopental — barbiturates suppress airway reflexes more completely than any other IV induction agent, abolishing the laryngospasm and bronchospasm triggered by laryngoscopy and intubation, making thiopental the preferred agent when airway reactivity is the primary concern.
E) Dexmedetomidine — its alpha-2 agonist mechanism reduces sympathetic tone throughout the airway, suppressing both adrenergic bronchoconstriction and the catecholamine surge from laryngoscopy, providing the most stable airway environment during intubation in a bronchospastic patient.
ANSWER: B
Rationale:
Option B is correct. Ketamine is the induction agent of choice for emergency intubation in acute severe asthma. Its bronchodilatory effect is well established and operates primarily through its sympathomimetic mechanism: by stimulating catecholamine release and inhibiting reuptake, ketamine increases adrenergic tone at airway smooth muscle, where beta-2 adrenergic receptor activation produces bronchodilation. There may also be a component of direct smooth muscle relaxation. The combined cardiovascular stimulation (preventing induction-related hypotension) and bronchodilation (reducing or reversing bronchospasm) make ketamine uniquely appropriate when the primary threat is bronchospasm requiring intubation.
Option A: Option A is incorrect; propofol does not produce bronchodilation through GABA-A-mediated vagal inhibition — while propofol has some evidence of mild bronchodilatory or at least airway-neutral properties at clinical doses, the mechanism described is inaccurate and the effect is not equivalent to ketamine's bronchodilation; propofol's cardiovascular depression is an additional liability in a patient already physiologically stressed by severe asthma.
Option C: Option C is incorrect; while etomidate is hemodynamically stable, it is not bronchospasm-neutral in the sense of providing active bronchodilation — it lacks the direct bronchodilatory property that makes ketamine specifically advantageous in this setting; hemodynamic stability alone is not the primary selection criterion when airway bronchospasm is the dominant problem.
Option D: Option D is incorrect; thiopental is actually associated with histamine release and bronchospasm — it is relatively contraindicated in asthmatic patients precisely because it can worsen airway reactivity, not attenuate it; the claim of superior airway reflex suppression is pharmacologically inaccurate for thiopental in this context.
Option E: Option E is incorrect; dexmedetomidine's alpha-2 mechanism reduces sympathetic tone, which would reduce beta-2 adrenergic bronchodilation rather than enhance it — reducing adrenergic drive in a bronchospastic patient is pharmacologically counterproductive, and dexmedetomidine is not used for emergency induction for intubation.
4. During administration of a dexmedetomidine loading infusion, the nurse reports that the patient's blood pressure has transiently increased before subsequently falling below baseline. Which mechanism explains this biphasic blood pressure response?
A) The loading infusion activates central alpha-2A receptors in the locus coeruleus before reaching peripheral receptors, producing an initial centrally-mediated hypertension from paradoxical sympathetic activation that resolves once peripheral sympatholysis becomes dominant.
B) The initial hypertension reflects a baroreceptor overshoot — dexmedetomidine's central sympatholytic effect reduces heart rate so abruptly that cardiac output falls, triggering a reflex peripheral vasoconstriction that transiently raises MAP before the central effect fully establishes itself.
C) The biphasic response is an artifact of the monitoring — the transient pressure rise is caused by the patient responding to the discomfort of the loading infusion rate, producing a pain-mediated catecholamine surge before the sedative effect suppresses that response.
D) Dexmedetomidine activates cardiac alpha-2B receptors during the loading phase, producing a direct positive inotropic effect and transiently increasing cardiac output and MAP before the drug redistributes to the vasculature and produces its sustained vasodilatory effect.
E) During the loading infusion, high dexmedetomidine concentrations activate peripheral alpha-2B adrenergic receptors in vascular smooth muscle, producing vasoconstriction and a transient blood pressure rise before drug reaches the locus coeruleus; as the central sympatholytic effect is established, norepinephrine release is suppressed and blood pressure falls to the sustained lower level characteristic of dexmedetomidine maintenance infusion.
ANSWER: E
Rationale:
Option E is correct. Dexmedetomidine's biphasic blood pressure response is a direct consequence of the drug reaching different anatomical targets at different rates during the loading infusion. Peripheral alpha-2B adrenergic receptors in vascular smooth muscle are activated first as drug enters the circulation, producing vasoconstriction and a transient rise in systemic vascular resistance and MAP. As drug concentration builds in the brain and reaches the locus coeruleus, central alpha-2A receptor activation hyperpolarizes noradrenergic neurons and suppresses norepinephrine release throughout the brain and sympathetic nervous system — this central sympatholysis reduces heart rate and blood pressure, and the sustained hemodynamic state of the maintenance infusion is characterized by lower MAP and bradycardia rather than the initial hypertensive phase. This sequence explains why the loading infusion is administered slowly (over 10 minutes) and why bolus dosing is avoided — rapid high-concentration delivery would exaggerate the peripheral vasoconstrictor phase.
Option A: Option A is incorrect; the initial hypertension is peripheral (vascular smooth muscle alpha-2B activation), not a paradoxical central sympathetic activation — the locus coeruleus response produces sympatholysis, not stimulation.
Option B: Option B is incorrect; the baroreceptor overshoot mechanism described — wherein heart rate reduction triggers reflex peripheral vasoconstriction sufficient to raise MAP — is not the established explanation for dexmedetomidine's biphasic response; baroreceptor reflexes would be expected to produce tachycardia in response to falling MAP, not vasoconstriction producing hypertension.
Option C: Option C is incorrect; the biphasic response is a reproducible pharmacological property of dexmedetomidine attributable to its receptor pharmacology, not a monitoring artifact or pain response.
Option D: Option D is incorrect; dexmedetomidine does not activate cardiac alpha-2B receptors to produce positive inotropy — the drug's cardiac effects are rate-reducing (bradycardia), not inotropic, and are mediated through central sympatholysis and vagally-mediated slowing.
5. Which statement most accurately describes the clinically important formulation properties of propofol that govern its safe preparation and administration?
A) Propofol is formulated as an aqueous solution with a pH of 3.5 to 4.5, which accounts for its pain on injection into small veins and its incompatibility with alkaline medications in the same IV line — the acidic pH does not support bacterial growth, and opened vials may be used for up to 24 hours if kept refrigerated.
B) Propofol's lipid emulsion vehicle contains medium-chain triglycerides that are metabolized rapidly by adipose tissue lipoprotein lipase, eliminating any meaningful caloric contribution at standard procedural sedation doses; the primary formulation concern is its osmolarity, which is high enough to cause hemolysis if administered without adequate dilution.
C) Propofol is formulated in a lipid emulsion (10% soybean oil, 1.2% egg phosphatide, 2.25% glycerol) that supports bacterial growth if contaminated; strict aseptic technique is required during preparation and administration, and opened vials should be used within 6 to 12 hours per manufacturer guidance. The lipid vehicle contributes approximately 1.1 kcal/mL, which must be accounted for in nutritional calculations during prolonged ICU infusions.
D) Propofol is supplied as a lyophilized powder reconstituted with sterile water immediately before use, producing a milky white solution; the reconstituted preparation must be used within 2 hours and cannot be stored because the reconstituted emulsion is thermodynamically unstable and will phase-separate at room temperature.
E) Propofol's lipid emulsion is identical in composition to total parenteral nutrition fat emulsions and can therefore be co-administered through the same IV line as parenteral nutrition without compatibility concerns, provided the combined infusion rate does not exceed the patient's maximum lipid clearance capacity.
ANSWER: C
Rationale:
Option C is correct. Propofol's formulation has several clinically important properties that directly govern safe use. It is an oil-in-water lipid emulsion containing 10% soybean oil, 1.2% egg phosphatide as an emulsifier, and 2.25% glycerol — this lipid-rich vehicle supports bacterial growth if the vial is contaminated or if sterile technique is not maintained during preparation and handling. Opened vials must therefore be discarded within 6 to 12 hours per manufacturer guidance, and strict aseptic technique is mandatory. The caloric density of approximately 1.1 kcal/mL is clinically significant in ICU patients receiving prolonged high-dose infusions — a patient receiving 4 mg/kg/hr of propofol is receiving approximately 400 mL/hr of the emulsion, contributing a substantial and easily overlooked caloric load that, if not accounted for, can lead to overfeeding.
Option A: Option A is incorrect; propofol is an oil-in-water emulsion, not an aqueous solution — it does not have a low pH of 3.5 to 4.5, and the 24-hour discard window after refrigeration is inconsistent with manufacturer guidance, which specifies shorter periods.
Option B: Option B is incorrect; propofol's emulsion contains long-chain triglycerides (soybean oil), not medium-chain triglycerides; the caloric contribution is clinically meaningful, particularly during prolonged ICU infusions; osmolarity is not the primary formulation safety concern.
Option D: Option D is incorrect; propofol is not supplied as a lyophilized powder — it is a pre-formulated lipid emulsion supplied in vials or prefilled syringes ready for administration.
Option E: Option E is incorrect; propofol emulsion is not compatible for co-administration in the same line as total parenteral nutrition — incompatibilities and contamination risks make dedicated IV access for propofol standard practice; the two formulations are not interchangeable in the same line.
6. Ketamine has historically been considered contraindicated in patients with elevated intracranial pressure (ICP). How has contemporary evidence modified this position?
A) Ketamine increases cerebral blood flow, cerebral metabolic rate, and ICP through its sympathomimetic properties and direct cerebral vasodilation — this remains a concern in spontaneously breathing patients with known elevated ICP; however, in mechanically ventilated patients with controlled ventilation (preventing the hypercapnia that amplifies ketamine's cerebral effects), multiple retrospective and prospective studies have found the ICP increase to be modest and manageable, and the categorical contraindication in ventilated TBI patients has been substantially revised.
B) Contemporary evidence has fully rehabilitated ketamine for all patients with elevated ICP — large randomized trials in traumatic brain injury have demonstrated that ketamine's NMDA antagonism is actually cerebroprotective, reducing excitotoxic glutamate-mediated neuronal injury and improving neurological outcomes, making it now the preferred agent for sedation in all TBI patients regardless of ventilatory status.
C) The concern about ketamine and ICP was based entirely on studies using older formulations containing benzethonium chloride preservative, which caused cerebral vasoconstriction and falsely elevated measured ICP — current preservative-free ketamine formulations have no effect on cerebral hemodynamics and carry no ICP risk.
D) Contemporary evidence has confirmed that ketamine's ICP elevation is clinically significant in all patient populations, including ventilated patients — the absolute contraindication has been extended rather than revised, and ketamine should be avoided in any patient with or at risk for intracranial hypertension regardless of ventilatory management.
E) Ketamine's effect on ICP is mediated entirely through its opioid receptor agonism causing cerebral vasodilation — co-administration of naloxone at a dose of 0.4 mg IV completely blocks this effect without affecting the NMDA-mediated anesthetic properties, making ketamine safe in all ICP-elevated patients when combined with naloxone pretreatment.
ANSWER: A
Rationale:
Option A is correct. Ketamine's cerebral hemodynamic effects — increased cerebral blood flow (CBF), cerebral metabolic rate for oxygen (CMRO2), and ICP — are mediated through its sympathomimetic properties (increasing systemic MAP and cerebral perfusion pressure) and possibly through direct cerebral vasodilation. The traditional categorical contraindication in elevated ICP arose from concerns about these effects in spontaneously breathing patients, where concurrent hypercapnia (from any degree of respiratory depression) amplifies cerebral vasodilation and further elevates ICP. The important contemporary revision is that in mechanically ventilated patients with controlled normocarbia, the ICP increase with ketamine appears modest and clinically manageable — numerous retrospective series and prospective studies in ventilated traumatic brain injury patients have found ketamine safe for procedural sedation and analgesia, and several guidelines have softened or removed the blanket contraindication specifically for ventilated patients. The contraindication remains reasonable clinical practice in spontaneously breathing patients with known elevated ICP.
Option B: Option B is incorrect; ketamine has not been validated as universally cerebroprotective by large randomized trials — while its NMDA antagonism is theoretically neuroprotective in the context of excitotoxicity, this has not translated into demonstrated outcome benefit, and it is not the preferred agent for all TBI patients.
Option C: Option C is incorrect; the historical ICP concern was based on ketamine's pharmacological effects, not on benzethonium chloride preservative — preservative is not the explanation for the cerebral hemodynamic effects.
Option D: Option D is incorrect; the contemporary evidence trend is toward revision and softening of the contraindication in ventilated patients, not extension to all populations — this option states the opposite of what the evidence shows.
Option E: Option E is incorrect; ketamine's ICP effects are not mediated through opioid receptor agonism, and naloxone co-administration does not abolish its cerebral hemodynamic effects — this described protocol does not exist in clinical practice.
7. Thiopental is supplied as a highly alkaline solution (pH approximately 10.5) when reconstituted for clinical use. Which serious complication arises specifically from this physicochemical property, and what is the immediate management?
A) Inadvertent subcutaneous extravasation of thiopental causes a benign local inflammatory reaction that resolves spontaneously within 48 to 72 hours — no specific treatment is required beyond applying a warm compress to promote local absorption of the alkaline solution.
B) The alkaline pH of thiopental causes precipitation of calcium in the veins proximal to the injection site, producing a thrombophlebitis syndrome that mimics deep vein thrombosis — treatment requires systemic anticoagulation with heparin to prevent extension of the thrombotic process.
C) Thiopental's alkalinity causes direct damage to red blood cell membranes if the pH of the infusate exceeds 9.0, producing intravascular hemolysis and hemoglobinuria — management requires immediate fluid resuscitation and alkalinization of urine to prevent hemoglobin cast formation in renal tubules.
D) Inadvertent intraarterial injection of thiopental causes intense burning pain, arterial spasm, crystal formation within the vessel lumen, and potentially limb-threatening ischemia — because the highly alkaline solution precipitates in the acidic arterial environment, crystalline deposits form within the arterial lumen causing mechanical obstruction alongside chemical endothelial injury; immediate treatment includes intra-arterial vasodilators and anticoagulation to preserve limb perfusion.
E) The high pH of thiopental causes irreversible protein precipitation at the injection site vein endothelium, producing a fibrous stricture within 24 hours that permanently occludes the vein — all subsequent IV access in the affected extremity must use vessels proximal to the stricture.
ANSWER: D
Rationale:
Option D is correct. Thiopental's high alkalinity (pH approximately 10.5 when reconstituted) makes inadvertent intraarterial injection a serious and potentially limb-threatening complication. When thiopental enters an artery, the highly alkaline solution precipitates in the relatively acidic arterial environment, forming crystals within the arterial lumen. This mechanical obstruction combines with intense chemical injury to the arterial endothelium, triggering arterial spasm, endothelial inflammation, and thrombosis. The patient experiences immediate intense burning pain at the injection site — an important early warning sign. If not recognized and treated promptly, the resulting ischemia can progress to limb loss. Immediate management includes recognizing the complication, leaving the inadvertent intraarterial cannula in place (to allow intra-arterial drug administration), instilling intra-arterial vasodilators (papaverine, lidocaine, or phentolamine), initiating systemic anticoagulation with heparin to prevent thrombotic propagation, and obtaining urgent vascular surgery consultation.
Option A: Option A is incorrect; subcutaneous extravasation of thiopental is not benign — the highly alkaline solution causes tissue necrosis, not a mild inflammatory reaction — but intraarterial injection is the far more serious complication and the scenario specifically describes the consequences of the alkaline pH in a vascular context.
Option B: Option B is incorrect; thiopental's alkalinity does not cause intravascular calcium precipitation producing DVT-like thrombophlebitis — the serious vascular complication is intraarterial injection, not calcium precipitation in veins.
Option C: Option C is incorrect; thiopental does not cause intravascular hemolysis through red blood cell membrane damage at clinical concentrations — this mechanism is fabricated.
Option E: Option E is incorrect; while extravasation can cause local tissue injury, permanent fibrous vein stricture requiring proximal access is not an established consequence of thiopental injection — the described complication is pharmacologically inaccurate.
8. A patient with end-stage renal disease on hemodialysis receives midazolam for procedural sedation. Despite standard dosing, sedation is markedly prolonged — the patient remains somnolent 6 hours after administration. Which pharmacokinetic mechanism explains this finding?
A) Renal failure reduces the volume of distribution of midazolam by decreasing plasma protein binding — because midazolam is highly protein-bound to albumin, hypoalbuminemia in renal failure increases the free fraction, raising free plasma concentrations and prolonging effect despite standard total drug doses.
B) Midazolam is hepatically metabolized by CYP3A4 (cytochrome P450 3A4) to 1-hydroxymidazolam, an active metabolite with approximately 10% of the potency of the parent compound; 1-hydroxymidazolam is subsequently glucuronidated to 1-hydroxymidazolam glucuronide, which is renally excreted. In patients with renal failure, this glucuronide metabolite accumulates to high concentrations, prolonging sedation beyond what would be expected from the parent drug alone.
C) Renal failure impairs CYP3A4 activity in the liver through accumulation of uremic toxins that competitively inhibit the enzyme — midazolam metabolism is therefore substantially slowed, parent drug concentrations remain elevated, and sedation is prolonged through direct accumulation of the unmetabolized parent compound.
D) Hemodialysis removes midazolam from the plasma compartment during each dialysis session, but the large volume of distribution causes rapid rebound of plasma concentrations from peripheral tissue stores after dialysis — the prolonged sedation reflects post-dialysis plasma rebound rather than metabolite accumulation.
E) Midazolam undergoes significant renal tubular secretion as the unmodified parent compound in patients with preserved renal function — in renal failure, this elimination pathway is lost and the drug follows exclusively hepatic metabolism, which is slower, resulting in markedly prolonged half-life of the parent drug.
ANSWER: B
Rationale:
Option B is correct. Midazolam itself is primarily hepatically metabolized by CYP3A4 to 1-hydroxymidazolam, and hepatic function is not significantly impaired in isolated renal failure — so the parent drug's metabolism proceeds normally. The clinically important mechanism of prolonged sedation in renal failure is the accumulation of 1-hydroxymidazolam glucuronide. After 1-hydroxymidazolam is formed in the liver, it undergoes glucuronidation (a phase II conjugation reaction) to produce 1-hydroxymidazolam glucuronide, which retains approximately 10% of the pharmacological activity of midazolam and is excreted renally. In patients with renal failure, this active glucuronide metabolite cannot be cleared and accumulates to concentrations that sustain benzodiazepine receptor occupancy and sedation long after the parent drug has been eliminated. This is an important clinical consideration: midazolam may appear to have a much longer duration of action in patients with renal impairment than in patients with normal renal function, and dose reductions are appropriate.
Option A: Option A is incorrect; while hypoalbuminemia in renal failure does increase the free fraction of midazolam, midazolam has a large volume of distribution and this effect does not account for 6-hour prolonged sedation — the dominant mechanism is active metabolite accumulation.
Option C: Option C is incorrect; renal failure does not substantially impair hepatic CYP3A4 activity through uremic toxin inhibition at a clinically meaningful level — CYP3A4 remains functional, and midazolam metabolism proceeds at near-normal rates; the prolonged sedation is from metabolite accumulation, not CYP3A4 inhibition.
Option D: Option D is incorrect; midazolam's large volume of distribution means it is not effectively cleared by hemodialysis — the described post-dialysis rebound is not the mechanism of prolonged sedation; the active metabolite mechanism is the established explanation.
Option E: Option E is incorrect; midazolam does not undergo significant renal tubular secretion as the parent compound — its elimination is almost entirely hepatic, and the renal pathway relevant to its sedative duration is glucuronide metabolite excretion, not parent drug secretion.
9. Propofol is preferred over volatile halogenated anesthetic agents for neuroanesthetic applications requiring control of cerebral hemodynamics. Which property of propofol's CNS effects most directly explains this preference?
A) Propofol abolishes cerebral autoregulation (the intrinsic ability of cerebral vessels to maintain constant CBF across a range of perfusion pressures) at induction doses, producing a maximally vasodilated cerebral vasculature that is unresponsive to changes in blood pressure — this fixed low-resistance state simplifies neuroanesthetic management by eliminating pressure-dependent CBF variability.
B) Propofol increases cerebral metabolic rate for oxygen (CMRO2) while simultaneously reducing cerebral blood flow (CBF), producing a favorable extraction reserve that protects against ischemia during periods of temporary vascular occlusion in cerebrovascular surgery.
C) Propofol's cerebral effects are entirely mediated through systemic blood pressure reduction — because it lowers MAP, less blood is delivered to the cerebral circulation at any given intracranial pressure, reducing CBF and ICP through a purely hemodynamic mechanism without any direct cerebrovascular action.
D) Propofol causes cerebral vasodilation equivalent to that produced by volatile agents at equi-potent doses, but its simultaneous reduction in CMRO2 is proportionally greater than the vasodilatory effect, producing a net reduction in CBF and ICP — the magnitude of CMRO2 suppression rather than direct vascular action is the mechanism of its neuroanesthetic advantage.
E) Propofol reduces CMRO2 and CBF in a coupled, dose-dependent fashion — unlike volatile agents, it does not cause cerebral vasodilation, so the reduction in CBF parallels the reduction in CMRO2 and cerebrovascular coupling (the relationship between metabolic demand and blood flow) is preserved; at clinical infusion rates propofol also preserves cerebral autoregulation better than volatile agents at equivalent depths of anesthesia.
ANSWER: E
Rationale:
Option E is correct. Propofol's neuroanesthetic advantage rests on two related properties. First, it reduces CMRO2 and CBF in a coupled fashion — unlike volatile halogenated agents, which cause direct cerebral vasodilation independent of metabolic demand (uncoupling metabolism from flow), propofol produces parallel reductions in both CMRO2 and CBF, preserving cerebrovascular coupling. This means that as the brain's metabolic rate falls under propofol, blood flow falls proportionally, and the autoregulatory relationship between perfusion pressure and CBF remains intact. Second, at clinical maintenance concentrations, propofol preserves cerebral autoregulation better than volatile agents at equivalent depths of anesthesia — this is important during neurosurgery where blood pressure fluctuations are common and the ability of the brain to compensate for changes in perfusion pressure is clinically valuable. These properties make propofol-based TIVA favorable for procedures such as cerebral aneurysm repair, carotid endarterectomy, and tumor resection near eloquent cortex.
Option A: Option A is incorrect; propofol does not abolish cerebral autoregulation at induction doses — in fact, preservation of autoregulation is one of its advantages over volatile agents; the described maximally vasodilated fixed state is the opposite of propofol's effect.
Option B: Option B is incorrect; propofol reduces both CMRO2 and CBF — it does not increase CMRO2 while reducing CBF; the described extraction reserve mechanism is pharmacologically inaccurate.
Option C: Option C is incorrect; propofol does have direct cerebrovascular effects through its CNS mechanism — the reduction in CMRO2 drives a coupled reduction in CBF through metabolic autoregulation, which is distinct from and in addition to any hemodynamic effects on systemic MAP.
Option D: Option D is incorrect; propofol does not cause cerebral vasodilation — this is the key distinction from volatile agents; the premise of the option is wrong.
10. A patient is undergoing right lower lobectomy requiring one-lung ventilation (OLV) — a technique in which the operative lung is collapsed to allow surgical access, with ventilation maintained through the dependent lung only. The thoracic anesthesiologist elects to use TIVA with propofol and remifentanil rather than volatile agent maintenance during the OLV period. Which physiological principle most directly supports this choice?
A) Propofol produces greater bronchodilation of the dependent ventilated lung than volatile agents, reducing airway resistance and improving tidal volume delivery to the lung responsible for gas exchange, thereby enhancing oxygenation during OLV.
B) Volatile halogenated agents reduce pulmonary vascular resistance throughout the lung vasculature, increasing right ventricular preload during OLV and producing right heart strain that propofol does not cause — TIVA is therefore chosen to protect right ventricular function during the period of elevated pulmonary vascular resistance from OLV.
C) Propofol does not inhibit hypoxic pulmonary vasoconstriction (HPV — the reflex constriction of pulmonary arterioles supplying poorly ventilated or collapsed alveoli, which diverts blood flow away from hypoxic lung regions toward ventilated regions), whereas volatile halogenated agents attenuate HPV in proportion to their inspired concentration; during OLV, preserving HPV in the collapsed operative lung reduces intrapulmonary shunt and maintains oxygenation.
D) TIVA with propofol reduces cerebral oxygen consumption, and this systemic reduction in total body oxygen demand is sufficient to compensate for the increased intrapulmonary shunt during OLV, maintaining acceptable arterial oxygen saturation without any change in pulmonary hemodynamics.
E) Volatile agents cause preferential vasodilation of pulmonary veins rather than arterioles during OLV, increasing pulmonary venous pressure and producing hydrostatic pulmonary edema in the dependent ventilated lung — propofol's pulmonary vascular neutrality prevents this complication.
ANSWER: C
Rationale:
Option C is correct. Hypoxic pulmonary vasoconstriction (HPV) is a critical homeostatic reflex that directs blood flow away from poorly ventilated or collapsed lung regions toward well-ventilated regions, thereby minimizing intrapulmonary shunt and preserving arterial oxygenation. During one-lung ventilation, the operative (collapsed) lung is not being ventilated — HPV in that lung's vasculature reduces blood flow through the non-ventilated region and redirects it to the ventilated dependent lung, reducing the shunt fraction and improving PaO2. Volatile halogenated anesthetic agents are well established to attenuate HPV in a dose-dependent fashion — at clinical maintenance concentrations (0.5 MAC and above), they blunt HPV sufficiently to increase shunt fraction and worsen oxygenation during OLV. Propofol does not inhibit HPV and therefore does not impair this compensatory mechanism; TIVA during OLV is associated with better-preserved oxygenation compared to volatile agent maintenance in multiple studies of thoracic anesthesia.
Option A: Option A is incorrect; while ketamine is a bronchodilator, propofol does not produce clinically significant bronchodilation that would selectively improve dependent lung ventilation — this is not the mechanism supporting TIVA in OLV.
Option B: Option B is incorrect; volatile agents reduce overall pulmonary vascular resistance (not increase it), and right heart strain during OLV is driven by increased resistance in the non-ventilated lung from HPV, not from volatile agent effects — the described mechanism is pharmacologically inverted.
Option D: Option D is incorrect; propofol's reduction in cerebral CMRO2 does not meaningfully reduce total body oxygen demand sufficiently to compensate for increased intrapulmonary shunt — the relevant physiological mechanism is pulmonary hemodynamics, not systemic oxygen consumption.
Option E: Option E is incorrect; volatile agents do not cause selective pulmonary venous vasodilation producing hydrostatic edema in the dependent lung — this mechanism is fabricated.
11. Processed electroencephalography (pEEG) monitoring — including the bispectral index (BIS), which provides a dimensionless index from 0 (isoelectric) to 100 (fully awake) derived from EEG signal analysis — is used to guide anesthetic depth during TIVA. Which statement correctly characterizes its clinical application and the evidence supporting its use?
A) The BIS target range for surgical anesthesia is 40 to 60; TIVA-based anesthesia without depth monitoring carries an intraoperative awareness risk of approximately 1 in 500 to 1 in 1,000 compared to approximately 1 in 10,000 to 1 in 30,000 for volatile agent-based anesthesia — pEEG monitoring reduces awareness incidence in high-risk TIVA cases by approximately 50 to 80% and is considered standard of care for TIVA in many centers.
B) The BIS target for surgical anesthesia is 60 to 80 — values below 60 indicate excessive depth associated with postoperative cognitive dysfunction, and the primary purpose of BIS monitoring in TIVA is to prevent overdosing rather than to detect awareness.
C) BIS monitoring is equally effective for guiding both TIVA and volatile agent-based anesthesia — the clinical evidence shows identical awareness risk reduction in both settings, and any difference in awareness incidence between TIVA and volatile techniques disappears when BIS guidance is applied.
D) Because BIS is derived from a single-channel frontal EEG, it provides reliable anesthetic depth information only during propofol-based anesthesia and produces artifactual readings during volatile agent maintenance — its use should therefore be restricted to TIVA cases and avoided during inhalational anesthesia.
E) Processed EEG monitoring has been shown in large multicenter trials to increase rather than decrease awareness incidence during TIVA — the alarm thresholds cause clinicians to reduce propofol infusion rates in response to falsely elevated BIS values, producing light anesthesia planes that would not have occurred with standard weight-based infusion protocols.
ANSWER: A
Rationale:
Option A is correct. The BIS target range of 40 to 60 for surgical anesthesia is the standard clinical guideline — values below 40 indicate excessive depth (risk of hemodynamic depression and prolonged emergence), while values above 60 during surgery indicate insufficient depth (risk of awareness and response to stimulation). The awareness risk differential between TIVA and volatile anesthesia is clinically important: without depth monitoring, TIVA carries an estimated awareness incidence of approximately 1 in 500 to 1 in 1,000, substantially higher than volatile agent-based anesthesia (approximately 1 in 10,000 to 1 in 30,000), because the end-tidal gas concentration that serves as a reliable continuous pharmacodynamic surrogate for volatile agent depth is absent in TIVA. The B-Aware trial demonstrated a significant reduction in awareness with BIS monitoring in high-risk patients, and meta-analyses support approximately 50 to 80% reduction in awareness in high-risk TIVA cases. pEEG monitoring is considered standard of care for TIVA in many international anesthetic guidelines and most major teaching centers.
Option B: Option B is incorrect; the BIS target for surgical anesthesia is 40 to 60, not 60 to 80 — values in the 60 to 80 range typically indicate sedation rather than surgical anesthesia, and the primary application in TIVA is ensuring adequate depth to prevent awareness, not exclusively preventing overdose.
Option C: Option C is incorrect; the evidence supporting pEEG monitoring is strongest specifically for TIVA — the awareness reduction benefit is greatest where the risk of awareness without monitoring is highest; volatile agent-based anesthesia already has a lower baseline awareness risk through end-tidal monitoring, so the incremental benefit of pEEG is less pronounced.
Option D: Option D is incorrect; BIS is used in both TIVA and volatile agent-based anesthesia and is not restricted to propofol — it processes frontal EEG signals that reflect anesthetic depth from multiple agent classes, though its utility is greatest in TIVA.
Option E: Option E is incorrect; this directly inverts the evidence — pEEG monitoring has been shown to reduce, not increase, awareness incidence in high-risk populations; the clinical concern about BIS is not that it increases awareness but that its predictive accuracy is imperfect and that pharmacokinetic variability requires clinical endpoints alongside BIS targets.
12. The use of etomidate for induction of anesthesia or procedural sedation in patients with septic shock remains clinically debated. Which statement most accurately reflects the current state of evidence and practice?
A) The debate has been definitively resolved by multiple large randomized controlled trials demonstrating that etomidate does not worsen outcomes in septic shock patients — adrenal suppression from a single induction dose is subclinical and has no measurable effect on vasopressor requirements, ICU length of stay, or mortality.
B) Etomidate is now formally contraindicated by the Surviving Sepsis Campaign guidelines in all patients with septic shock, regardless of the urgency of the indication — the guideline recommendation is based on level A evidence from randomized trials demonstrating increased 28-day mortality attributable to single-dose etomidate-induced adrenal suppression.
C) The concern about etomidate in septic shock applies only to patients who have already received exogenous corticosteroids — in steroid-naive septic patients, the adrenal axis is functioning normally and etomidate's suppression of 11-beta-hydroxylase does not produce clinically meaningful cortisol deficiency because baseline cortisol production is sufficient to buffer the enzymatic inhibition.
D) The evidence remains genuinely debated — multiple randomized trials and meta-analyses have examined etomidate's impact in septic patients, with some showing increased ICU mortality or vasopressor requirements and others showing no significant difference after adjustment for confounders; the standing clinical recommendation in many centers is to avoid etomidate in patients with known or suspected adrenal insufficiency and to consider ketamine as a hemodynamically stable alternative, particularly in septic shock where adrenal reserve may already be compromised.
E) Single-dose etomidate produces adrenal suppression only in patients who are also receiving CYP3A4 inhibitors — because etomidate is metabolized by the same pathway as cortisol's synthetic enzymes, CYP3A4 inhibitors (such as fluconazole or clarithromycin) dramatically amplify etomidate's 11-beta-hydroxylase inhibition, and the sepsis concern applies exclusively to patients on these agents.
ANSWER: D
Rationale:
Option D is correct. The clinical debate surrounding etomidate in septic shock is genuine and unresolved, and accurately characterizing its nuance is important for clinical decision-making. Etomidate produces dose-dependent inhibition of 11-beta-hydroxylase (CYP11B1), suppressing cortisol production for 6 to 48 hours after a single induction dose. In patients with septic shock — where adrenal responsiveness is frequently already compromised, and where adequate cortisol production is important for the pressor response to catecholamines and hemodynamic stability — even transient adrenal suppression may be harmful. The published literature includes meta-analyses and individual trials on both sides: some showing increased ICU mortality and prolonged vasopressor dependence in etomidate-exposed septic patients, others showing no significant outcome difference after statistical adjustment. The practical result is that many centers now prefer ketamine as the hemodynamically stable induction alternative in septic shock, reserving etomidate for settings where ketamine is not suitable. This is not a categorical evidence-based ban but a reasonable precautionary practice reflecting the uncertainty.
Option A: Option A is incorrect; the debate has not been definitively resolved by large RCTs demonstrating safety — the evidence remains mixed and the debate is ongoing.
Option B: Option B is incorrect; the Surviving Sepsis Campaign does not issue a formal contraindication to etomidate based on level A evidence — this overstates both the strength of evidence and the firmness of the guideline position.
Option C: Option C is incorrect; the concern about etomidate in septic shock applies to all septic patients, not exclusively those on exogenous corticosteroids — septic shock itself compromises the adrenal axis independently of prior steroid exposure.
Option E: Option E is incorrect; etomidate's adrenal suppression operates through direct inhibition of CYP11B1 within the adrenal cortex, not through systemic CYP3A4-mediated drug interactions — CYP3A4 inhibitors do not amplify etomidate's steroidogenic enzyme inhibition through this mechanism.
13. Clinical trials comparing dexmedetomidine to midazolam-based sedation in mechanically ventilated ICU patients have demonstrated several outcome differences. Which finding most accurately reflects the evidence from these randomized trials?
A) Dexmedetomidine produces significantly deeper sedation than midazolam at equivalent doses, as measured by the Richmond Agitation-Sedation Scale (RASS — a validated 10-point scale from -5 deeply sedated to +4 combative, used to target sedation depth in the ICU), making it the preferred agent when prolonged deep sedation is required for patients with refractory agitation or high ventilatory requirements.
B) Compared to midazolam-based sedation, dexmedetomidine reduces the incidence of delirium (an acute brain dysfunction characterized by fluctuating attention, disorganized thinking, and altered consciousness), shortens the duration of mechanical ventilation, and facilitates earlier extubation — these benefits are attributed to its arousable, cooperative sedation quality and its avoidance of GABA-A-mediated global CNS suppression.
C) Dexmedetomidine and midazolam produce equivalent clinical outcomes in all measured endpoints in randomized trials — duration of ventilation, delirium incidence, length of ICU stay, and mortality — and the choice between them is therefore based on cost and institutional preference rather than evidence of differential clinical benefit.
D) Dexmedetomidine increases the risk of ventilator-associated pneumonia compared to midazolam because its arousable sedation quality results in more frequent patient self-extubation events requiring reintubation, negating the benefit of shorter ventilator duration seen with lighter sedation strategies.
E) Dexmedetomidine's primary advantage over midazolam in ICU trials is cardiovascular — it significantly reduces the incidence of atrial fibrillation and other supraventricular arrhythmias in postoperative cardiac surgery patients, while its effects on delirium and ventilator duration are no different from midazolam when patients are adequately sedated.
ANSWER: B
Rationale:
Option B is correct. The most important clinical trials comparing dexmedetomidine to benzodiazepine-based sedation in ventilated ICU patients — including the MENDS (Maximizing Efficacy of Targeted Sedation and Reducing Neurological Dysfunction) trial and the SEDCOM (Safety and Efficacy of Dexmedetomidine Compared with Midazolam) trial — demonstrated that dexmedetomidine-treated patients experienced less delirium, shorter duration of mechanical ventilation, and earlier extubation compared to midazolam-treated controls. The mechanistic explanation aligns with the pharmacology: dexmedetomidine's alpha-2-mediated locus coeruleus mechanism produces arousable, cooperative sedation resembling natural sleep, avoiding the global GABA-A-mediated CNS suppression of benzodiazepines that is associated with delirium and prolonged ventilator dependence. Its preservation of respiratory drive also facilitates weaning. These trial findings underpin current ICU sedation guidelines recommending non-benzodiazepine sedation (dexmedetomidine or propofol) over benzodiazepines in patients who do not require deep sedation.
Option A: Option A is incorrect; dexmedetomidine does not produce deeper sedation than midazolam — it targets RASS scores of -1 to -2 (light, arousable sedation) and is specifically unsuitable for situations requiring deep sedation; benzodiazepines are used when deep sedation is needed.
Option C: Option C is incorrect; the trials showed clinically meaningful and statistically significant differences favoring dexmedetomidine on delirium incidence and ventilator duration — outcomes are not equivalent.
Option D: Option D is incorrect; dexmedetomidine's lighter sedation does not cause increased ventilator-associated pneumonia from self-extubation — the clinical evidence does not support this outcome; lighter sedation strategies are generally associated with improved pulmonary outcomes.
Option E: Option E is incorrect; while dexmedetomidine does have cardiovascular protective effects including some evidence of reduced perioperative atrial fibrillation, the primary advantages demonstrated in ICU trials against midazolam are delirium reduction and shorter ventilation — not cardiovascular protection as the primary distinguishing endpoint.
14. Target-controlled infusion (TCI) systems calculate and continuously adjust propofol infusion rates to achieve a specified target plasma or effect-site drug concentration. Which statement accurately describes the pharmacokinetic models and regulatory status of TCI?
A) TCI systems use a single universal pharmacokinetic model (the Marsh-Schnider unified model) validated across all patient populations — the clinician enters a target plasma concentration in mcg/mL and the pump calculates infusion rates using standardized weight-based parameters that do not vary by age, sex, or body composition.
B) TCI is FDA-approved in the United States for use with propofol and remifentanil — the Diprifusor system received FDA clearance in 2001, and weight-based manual infusion is now considered an inferior alternative that should only be used when TCI equipment is unavailable.
C) The Marsh model for propofol TCI targets effect-site concentration by incorporating the plasma-to-effect-site equilibration half-life (ke0 — the rate constant governing drug transfer between plasma and the brain) as a patient-specific covariate adjusted for age and lean body mass, whereas the Schnider model targets plasma concentration using only total body weight.
D) In TCI systems targeting effect-site concentration, the pump transiently overshoots the target plasma concentration above the specified effect-site target in order to drive drug into the biophase (brain) more rapidly — this overshoot is intentional and its magnitude is determined by the ke0 value for the chosen pharmacokinetic model.
E) For propofol TCI, both the Marsh and Schnider pharmacokinetic models are widely used but have different covariate structures — the Schnider model incorporates patient age and lean body mass as covariates that adjust pharmacokinetic parameters for individual patients, whereas the Marsh model uses total body weight as the primary scaling variable; TCI is not FDA-approved in the United States, where weight-based manual infusion is standard practice, though TCI is widely available in Europe, Canada, Australia, and many other countries.
ANSWER: E
Rationale:
Option E is correct. The Marsh and Schnider models are the two most widely used pharmacokinetic models for propofol TCI, and their structural differences are clinically relevant. The Schnider model incorporates age and lean body mass (in addition to total body weight and height) as patient-specific covariates that adjust the pharmacokinetic parameters — volume of distribution, clearance, and inter-compartmental transfer rates — for individual patients, making it more individualized particularly in elderly patients and those at body composition extremes. The Marsh model uses total body weight as the primary scaling variable with fewer individual covariates. Regarding regulatory status: TCI systems using validated pharmacokinetic models are approved and widely used in the UK, Europe, Australia, Canada, and many other countries; however, they are not FDA-approved in the United States, where weight-based manual infusion (specifying an infusion rate in mcg/kg/min) is standard practice for TIVA maintenance.
Option A: Option A is incorrect; there is no single unified Marsh-Schnider model — these are two distinct pharmacokinetic models with different covariate structures; the characterization of a single universal model is inaccurate.
Option B: Option B is incorrect; TCI is not FDA-approved in the United States — this is a key regulatory distinction that every anesthesiologist should know; the Diprifusor system is CE-marked and used in Europe but did not receive broad FDA clearance for general use.
Option C: Option C is incorrect; this inverts the models — it is the Schnider model that incorporates age and lean body mass, and the Marsh model that uses primarily total body weight; additionally, both models can be run in either plasma-targeting or effect-site-targeting mode, and the covariate structure is a separate characteristic from the targeting mode.
Option D: Option D is incorrect; the description of intentional plasma overshooting in effect-site TCI mode is pharmacokinetically accurate — this is indeed a feature of effect-site targeting — but this option is not the best characterization of the full question because it omits the model comparison and regulatory context that the question specifically asks about; Option E provides the more complete and directly responsive answer to the question as asked.
15. Subanesthetic ketamine infusions have become an important component of opioid-sparing multimodal analgesia protocols in perioperative practice. Which statement most accurately describes the pharmacological rationale and evidence base for this application?
A) At subanesthetic doses, ketamine's primary analgesic mechanism is mu-opioid receptor agonism — it acts as a partial agonist at mu receptors with lower intrinsic efficacy than morphine but with a ceiling effect that prevents respiratory depression, making it a safer opioid alternative for patients at risk of respiratory compromise.
B) Subanesthetic ketamine reduces postoperative opioid consumption exclusively through its local anesthetic properties — at low infusion concentrations, ketamine blocks wound nociceptor sodium channels through the same mechanism as infiltrated lidocaine, reducing afferent pain signaling from the surgical site.
C) At subanesthetic doses (0.1 to 0.5 mg/kg IV bolus or 0.1 to 0.3 mg/kg/hr infusion), ketamine provides analgesia through NMDA receptor blockade, reducing central sensitization (wind-up of spinal dorsal horn neurons from repeated nociceptive input) and attenuating opioid-induced hyperalgesia (OIH — the paradoxical increase in pain sensitivity that can develop with prolonged high-dose opioid exposure, particularly remifentanil); evidence supports perioperative subanesthetic ketamine for reducing postoperative opioid consumption in major abdominal, thoracic, and orthopedic surgery.
D) Subanesthetic ketamine infusions are contraindicated in patients receiving remifentanil-based TIVA because the combined NMDA antagonism of ketamine and the kappa opioid receptor agonism of remifentanil produces a pharmacodynamic interaction that amplifies emergence reactions and hallucinations, increasing the incidence of postoperative delirium.
E) The analgesic benefit of subanesthetic ketamine is limited to the intraoperative period — once the infusion is stopped at the end of surgery, there is no residual postoperative analgesic effect because ketamine's NMDA antagonism does not produce lasting changes in central pain processing; any apparent reduction in postoperative opioid consumption in clinical trials is explained by propofol co-administration rather than ketamine's independent contribution.
ANSWER: C
Rationale:
Option C is correct. Subanesthetic ketamine has a well-characterized pharmacological rationale for perioperative analgesia. At doses well below those required for dissociative anesthesia — typically 0.1 to 0.5 mg/kg IV as a bolus or 0.1 to 0.3 mg/kg/hr as a continuous infusion — ketamine provides clinically meaningful analgesia with minimal sedation. The primary mechanism is NMDA receptor blockade, which reduces central sensitization: repeated nociceptive input from surgical trauma activates spinal NMDA receptors and drives progressive amplification of pain signaling (wind-up), and blocking these receptors attenuates this process. Ketamine also counteracts opioid-induced hyperalgesia — particularly relevant with remifentanil, where prolonged high-dose infusion sensitizes central pain pathways through NMDA-dependent mechanisms, producing postoperative pain intensity above what the surgical procedure alone would generate. Multiple randomized trials and meta-analyses support perioperative subanesthetic ketamine for reducing postoperative opioid consumption and pain scores in major abdominal, thoracic, and orthopedic surgery.
Option A: Option A is incorrect; subanesthetic ketamine's primary analgesic mechanism is NMDA receptor blockade, not mu-opioid receptor partial agonism — while ketamine does have opioid receptor activity, characterizing it as primarily a partial mu agonist at analgesic doses misrepresents its pharmacology and overstates its opioid receptor contribution at these concentrations.
Option B: Option B is incorrect; ketamine's perioperative analgesic effects operate through central NMDA-mediated mechanisms, not peripheral local anesthetic sodium channel blockade — the claimed wound infiltration-equivalent mechanism is pharmacologically inaccurate for IV subanesthetic infusions.
Option D: Option D is incorrect; subanesthetic ketamine is specifically used in combination with remifentanil-based TIVA to prevent OIH — it is not contraindicated in this setting; the described pharmacodynamic interaction producing amplified emergence reactions is fabricated.
Option E: Option E is incorrect; the analgesic benefit of perioperative ketamine does extend into the postoperative period — NMDA blockade reduces central sensitization during the surgical period, and this attenuation of spinal sensitization reduces postoperative pain intensity and opioid requirements; the clinical evidence for opioid-sparing is from ketamine as an independent contribution, not a propofol artifact.
16. Which of the following correctly describes the standard sequence and pharmacological rationale for ending a propofol-remifentanil TIVA technique at the conclusion of a surgical procedure?
A) Remifentanil is reduced or stopped at the time of wound closure to facilitate rapid emergence; transition to a longer-acting analgesic (IV morphine, fentanyl, or a regional technique) must be initiated before or immediately after stopping remifentanil to prevent the analgesic gap at emergence — because remifentanil provides no residual postoperative analgesia. Propofol is typically stopped 5 to 10 minutes before the planned end of the procedure. Dedicated IV access for the propofol infusion is important, as any interruption can cause rapid awakening given propofol's short context-sensitive half-time.
B) Propofol should be stopped first, 20 to 30 minutes before the planned end of procedure, to allow full hepatic clearance before remifentanil is stopped — if remifentanil is stopped before propofol is fully eliminated, the residual propofol concentrations will suppress the patient's drive to breathe, causing respiratory depression in the recovery room without adequate analgesic cover.
C) Both propofol and remifentanil should be stopped simultaneously at skin closure — the context-sensitive half-times of both agents are sufficiently short that simultaneous cessation produces smooth and near-simultaneous offset of hypnosis and analgesia, with the patient emerging already covered by the residual analgesic effect of remifentanil's slow terminal elimination phase.
D) Remifentanil must never be stopped before propofol during a TIVA case — the order of cessation is legally mandated in most jurisdictions because stopping remifentanil first while propofol is still running creates a state of opioid withdrawal under general anesthesia, which triggers severe autonomic instability and is classified as an anesthetic adverse event requiring incident reporting.
E) The standard approach is to increase the remifentanil infusion rate to 0.5 mcg/kg/min for the final 10 minutes of the case, using the high-dose opioid effect to ensure that the patient does not experience emergence pain during extubation — the remifentanil is then stopped at extubation, and its 3-to-5-minute offset provides a brief analgesic window sufficient to transport the patient to the recovery room before pain develops.
ANSWER: A
Rationale:
Option A is correct. The standard management of TIVA emergence integrates two pharmacological realities. First, remifentanil's ultra-short context-sensitive half-time (3 to 5 minutes) means its analgesic effect disappears within minutes of stopping the infusion, with no residual postoperative analgesia — this necessitates proactive transition to longer-acting analgesia before or at the time of stopping remifentanil, or the patient will emerge with full pain and no analgesic cover. This transition analgesia (IV morphine, fentanyl, paracetamol, NSAIDs, or regional techniques) must be administered with enough lead time for its onset to coincide with or precede remifentanil offset. Second, propofol's short CSHT (approximately 10 to 40 minutes depending on infusion duration) means stopping it 5 to 10 minutes before the end of the procedure produces reliable emergence timing. Dedicated IV access for propofol is emphasized because any inadvertent interruption — kinked line, disconnection, pump failure — immediately reduces propofol concentrations and can cause rapid awakening mid-procedure.
Option B: Option B is incorrect; the stated sequence — propofol 20 to 30 minutes before remifentanil — is incorrect; propofol is typically stopped last, not first, and 20 to 30 minutes of hepatic clearance is not the relevant timing concept; the concern about residual propofol suppressing respiratory drive is also pharmacologically exaggerated for this context.
Option C: Option C is incorrect; simultaneous cessation of both agents would create the analgesic gap — remifentanil has no terminal elimination phase providing residual analgesia; its offset is complete within minutes and there is no pharmacokinetic basis for the "slow terminal elimination" described.
Option D: Option D is incorrect; there is no legal mandate governing the order of TIVA agent cessation, and stopping remifentanil before propofol does not constitute opioid withdrawal under general anesthesia — this describes a fabricated regulatory and physiological scenario.
Option E: Option E is incorrect; using high-dose remifentanil (0.5 mcg/kg/min) for the final 10 minutes of the case to cover emergence actually increases the risk of OIH and analgesic gap — the 3-to-5-minute offset window is too brief to transport a patient to the recovery room and establish analgesic cover; this approach is pharmacologically counterproductive.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.